Document is current
Any future updates will be listed below
-
Authors
Rohanian, Morteza
Mehra, Tarun
Miglino, Nicola
Nooralahzadeh, Farhad
Krauthammer, Michael
Wicki, Andreas
-
Funding
Funding for this research was provided by:
Zurich Comprehensive Cancer Center
Digitalisierungsinitiative
Endowment of the professorship for oncology, University of Zurich
- License Information
-
More Information
Article History
Received: 2 June 2025
Accepted: 8 September 2025
First Online: 10 October 2025
Declarations
:
: Andreas Wicki reports funding from the Precision Oncology Program, a public-private partnership between University of Zurich, University Hospital Zurich, and Hoffmann-La Roche. Support for attending meetings and/or travel: Andreas Wicki received support from Amgen and ESMO 2022. Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Andreas Wicki serves as a Board Member of the Swiss Society of Medical Oncology and as Chair of the Human Medicines Expert Committee at the Swiss Agency for Therapeutic Products (Swissmedic). Morteza Rohanian declares no competing interests. Tarun Mehra declares no competing interests. Nicola Miglino declares no competing interests. Farhad Nooralahzadeh declares no competing interests. Michael Krauthammer declares no competing interests.
